Evidence map›Paper›PMID 37073374›Full record

ArticleiScience2023

COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series.

Sharon L Walmsley, Leah Szadkowski, Bradly Wouters, Rosemarie Clarke, Karen Colwill, Paula Rochon, Michael Brudno, Rizanni Ravindran, Janet Raboud, Allison McGeer and 10 more

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sharon L WalmsleyDepartment of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
Leah SzadkowskiBiostatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada.
Bradly WoutersPrincess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Rosemarie ClarkeDepartment of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
Karen ColwillLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Paula RochonWomen's College Hospital Research Institute, University of Toronto, Toronto, ON, Canada.
Michael BrudnoDepartment of Computer Science, University Health Network, University of Toronto, Toronto, ON, Canada.
Rizanni RavindranDepartment of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
Janet RaboudDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Allison McGeerDepartment of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Amit OzaPrincess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Christopher GrahamTrillium Health Partners, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Amanda SilvaDepartment of BioInformatics, University Health Network, University of Toronto, Toronto, ON, Canada.
Dorin ManaseDepartment of BioInformatics, University Health Network, University of Toronto, Toronto, ON, Canada.
Peter MaksymowskyDepartment of BioInformatics, University Health Network, University of Toronto, Toronto, ON, Canada.
Laura ParenteHealth Care Human Factors, University Health Network, University of Toronto, Toronto, ON, Canada.
Roaya Monica DayamLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Jacqueline SimpsonHealth Care Human Factors, University Health Network, University of Toronto, Toronto, ON, Canada.
Adrian PasculescuLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Anne-Claude GingrasLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a decentralized prospective cohort study of self-reported adverse events and antibody responses to COVID vaccines derived from dried blood spots. Data are presented for 911 older (aged >70 years) and 375 younger (30-50 years) recruits to 48 weeks after the primary vaccine series. After a single vaccine, 83% younger and 45% older participants had overall seropositivity (p < 0.0001) increasing to 100/98% with the second dose, respectively (p = 0.084). A cancer diagnosis (p = 0.009), no mRNA-1273 vaccine doses (p <0 .0001), and older age (p <0 .0001) predicted lower responses. Antibody levels declined in both cohorts at 12 and 24 weeks increasing with booster doses. At 48 weeks, for participants with 3 vaccine doses, the median antibody levels were higher in the older cohort (p = 0.04) with any dose of mRNA-1273 (p <0 .0001) and with COVID infection (p <0 .001). The vaccines were well tolerated. Breakthrough COVID infections were uncommon (16% older cohort, 29% younger cohort; p < 0.0001) and mild

Indexed as

Health sciencesImmune responseImmunologyMicrobiologyPublic health

Identifiers

PMID37073374
PMCPMC10043971

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read142
identifiers read13
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.